Literature DB >> 8207052

Hyaluronidase as an antidote to extravasation of Vinca alkaloids: clinical results.

G Bertelli1, D Dini, G B Forno, A Gozza, S Silvestro, M Venturini, R Rosso, P Pronzato.   

Abstract

Skin necrosis is a recognized potential consequence of an inadvertent extravasation of Vinca alkaloids in the surrounding tissues during i.v. administration. Experimental studies suggest that hyaluronidase, an enzyme that degrades hyaluronic acid and improves the absorption of locally injected drugs, can reduce the risk of progressing to skin necrosis. On this basis, we used this enzyme as a local treatment after extravasations of Vinca alkaloids in seven patients. No patient suffered from subsequent skin necrosis. To the best of our knowledge, this is the first clinical report confirming the positive findings of experimental studies on the effectiveness of this antidote.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8207052     DOI: 10.1007/bf01191807

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  4 in total

1.  Clinical uses of hyaluronidase; a current review.

Authors:  R C BRITTON; D V HABIF
Journal:  Surgery       Date:  1953-06       Impact factor: 3.982

Review 2.  Chemotherapy-induced emergencies.

Authors:  S M Schneider; C W Distelhorst
Journal:  Semin Oncol       Date:  1989-12       Impact factor: 4.929

Review 3.  Antidotes to vesicant chemotherapy extravasations.

Authors:  R T Dorr
Journal:  Blood Rev       Date:  1990-03       Impact factor: 8.250

4.  Vinca alkaloid skin toxicity: antidote and drug disposition studies in the mouse.

Authors:  R T Dorr; D S Alberts
Journal:  J Natl Cancer Inst       Date:  1985-01       Impact factor: 13.506

  4 in total
  15 in total

1.  A midline for oxaliplatin infusion: the myth of safety devices.

Authors:  Ben Masters; Tamas Hickish; Esther Uña Cidon
Journal:  BMJ Case Rep       Date:  2014-06-05

2.  Outcome of chemotherapy extravasation in a large patient series using a standardised management protocol.

Authors:  Ursula Pluschnig; Werner Haslik; Günther Bayer; Afschin Soleiman; Rupert Bartsch; Wolfgang Lamm; Günther G Steger; Christoph C Zielinski; Robert M Mader
Journal:  Support Care Cancer       Date:  2014-11-30       Impact factor: 3.603

Review 3.  Management of the extravasation of anti-neoplastic agents.

Authors:  J Boulanger; A Ducharme; A Dufour; S Fortier; K Almanric
Journal:  Support Care Cancer       Date:  2015-02-26       Impact factor: 3.603

4.  Determination of Extravasation Effects of Nal-Iri and Trabectedin and Evaluation of Treatment Options for Trabectedin Extravasation in a Preclinical Animal Model.

Authors:  Omar Keritam; Viktoria Juhasz; Christian Schöfer; Christiane Thallinger; Marie-Bernadette Aretin; Gernot Schabbauer; Johannes Breuss; Matthias Unseld; Pavel Uhrin
Journal:  Front Pharmacol       Date:  2022-06-03       Impact factor: 5.988

Review 5.  Prevention and management of extravasation of cytotoxic drugs.

Authors:  G Bertelli
Journal:  Drug Saf       Date:  1995-04       Impact factor: 5.606

Review 6.  [Extravasation of cytotoxic agents].

Authors:  Elisabeth Nogler-Semenitz; Ines Mader; Patrizia Fürst-Weger; Robert Terkola; Sabine Wassertheurer; Pietro Giovanoli; Robert M Mader
Journal:  Wien Klin Wochenschr       Date:  2004-05-31       Impact factor: 1.704

Review 7.  A review of clinical experience with paclitaxel extravasations.

Authors:  Brad L Stanford; Fred Hardwicke
Journal:  Support Care Cancer       Date:  2003-03-27       Impact factor: 3.603

Review 8.  Clinical Applications of Hyaluronidase.

Authors:  Gregor Cornelius Weber; Bettina Alexandra Buhren; Holger Schrumpf; Johannes Wohlrab; Peter Arne Gerber
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 2.622

9.  Extravasational side effects of cytotoxic drugs: A preventable catastrophe.

Authors:  Jagdeep S Thakur; C G S Chauhan; Vijay K Diwana; Dayal C Chauhan; Anamika Thakur
Journal:  Indian J Plast Surg       Date:  2008-07

10.  Extravasation injuries in adults.

Authors:  S Al-Benna; C O'Boyle; J Holley
Journal:  ISRN Dermatol       Date:  2013-05-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.